HOME › DRUGS › NATALIZUMAB
ACTIVE SUBSTANCE / INN

NATALIZUMAB

Brand name(s): Tyruko, Natalizumab Elan Pharma, Tysabri, TYSABRI
FDA LISTED
EMA LISTED
PRESCRIPTION
REFUSED
AUTHORISED
BLA125104
Multiple Sclerosis, Relapsing-Remitting;Multiple Sclerosis
ACTIVE SUBSTANCE
Natalizumab
REGULATORS
FDA · EMA
SPONSORS / MAH
Sandoz GmbH, BIOGEN IDEC, Biogen Netherlands B.V.
TOTAL APPLICATIONS
4
FDA APPLICATIONS (DRUGS@FDA)
BRAND NAMEAPPLICATIONSPONSORSTATUS
TYSABRIBLA125104BIOGEN IDECPrescription
EMA AUTHORISATIONS
PRODUCT NAMEHOLDERSTATUSDATEINDICATION
TyrukoSandoz GmbHAuthorised22/09/2023Multiple Sclerosis, Relapsing-Remitting;Multiple Sclerosis
TysabriBiogen Netherlands B.V.Authorised27/06/2006Multiple Sclerosis
Natalizumab Elan PharmaElan Pharma International Ltd.RefusedCrohn Disease

FULL INTELLIGENCE ON NATALIZUMAB

Patent cliffs, clinical trials, pipeline data, AI-enriched regulatory signals — free on PharmaSignal.

OPEN PLATFORM →